Results: Fourteen genes (CCL22, ADCY2, PDK1, ZFP36, CP, CD2, PLAUR, ACAP1, COL5A1, FAM83D, PBK, FANCA, ANXA7, and TACC3) were identified as genetic biomarkers that were all associated with pathways in glioma progression and drug resistance. This evidence concerns the gene CCL22 and central nervous system cancer.